LEXXW - Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24 2021 at 9:45 AM ET
(TheNewswire)
-
Lexaria recently announced progresson its hypertension R&D program, consisting of three humanclinical and two animal studies, as well as two studies in itsantiviral drug evaluation program
Kelowna, British Columbia – TheNewswire - March 22, 2021 –Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka ispresenting at the Benzinga Biotech Small Cap Conference to be held onMarch 24-25, 2021. Complimentary investor registration can be accessedthrough the conference link below.
Event registration link: Benzinga Biotech SmallCap Conference
Presentation date: March 24, 2021
Presentation time: 9:45 AM ET
Mr. Bunka will provide an overview of the Company,including its DehydraTECH™ drug delivery technology that improvesthe way active pharmaceutical ingredients enter the bloodstream. Hewill also discuss R&D programs that have been commenced toevaluate delivery effectiveness of DehydraTECH-processed cannabidiol(CBD) for hypertension, antiviral applications for SARS diseases andother infectious diseases, as well as other strategic initiatives.
Designed to bridge the gap between small-cap publiclytraded companies, investors and traders, the Benzinga Biotech SmallCap Conference enables executive leadership of small-cap biotechcompanies to network and communicate with a broad and diverse investorbase in a virtual setting.
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1 - 2 hours to minutes, and maskunwanted tastes; and is planned to be further evaluated for orallyadministered bioactive molecules, including anti-virals, cannabinoids,vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), andnicotine. Lexaria has licensed DehydraTECH to multiple companiesincluding a world-leading tobacco producer for the development ofsmokeless, oral-based nicotine products and for use in industries thatproduce cannabinoid beverages, edibles, and oral products. Lexariaoperates a licensed in-house research laboratory and holds a robustintellectual property portfolio with 18 patents granted andapproximately 60 patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this press release include, but are not limited to,statements by the company relating the Company’s ability to carryout research initiatives, receive regulatory approvals or grants orexperience positive effects or results from any research or study.Such forward-looking statements are estimates reflecting the Company'sbest judgment based upon current information and involve a number ofrisks and uncertainties, and there can be no assurance that theCompany will actually achieve the plans, intentions, or expectationsdisclosed in these forward-looking statements. As such, you shouldnot place undue reliance on these forward-looking statements. Factors whichcould cause actual results to differ materially from those estimatedby the Company include, but are not limited to, government regulationand regulatory approvals, managing and maintaining growth, the effectof adverse publicity, litigation, competition, scientific discovery,the patent application and approval process, potential adverse effectsarising from the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related topandemics, and other factors which may be identified from time to timein the Company's public announcements and periodic filings with the USSecurities and Exchange Commission on EDGAR. There is no assurancethat any of Lexaria’s postulated uses, benefits, or advantages forthe patented and patent-pending technology will in fact be realized inany manner or in any part. No statement herein has been evaluated bythe Food and Drug Administration (FDA). Lexaria-associated productsare not intended to diagnose, treat, cure or prevent any disease. Anyforward-looking statements contained in this release speak only as ofthe date hereof, and the Company expressly disclaims any obligation toupdate any forward-looking statements contained herein, whether as aresult of any new information, future events, changed circumstances orotherwise, except as otherwise required by law.
TheCSE has not reviewed and does not accept responsibility for theadequacy or accuracy of this release.
INVESTOR CONTACT:
Copyright (c) 2021 TheNewswire - All rights reserved.